natgillin/translations-raw huggingface dataset:
RTC: < 15 % blasts BM and PB, < 30 % blasts+promyelocytes in BM and PB, < 20 % basophils in PB, no extramedullary disease other than spleen and liver.
RTC: < 15 % blastov v BM in PB, < 30 % blastov+promielocitov v BM in PB, < 20 % bazofilcev v PB, brez obolelosti zunaj kostnega mozga, razen v vranici in jetrih.
RTC<15% blasts BM and PB, <30% blasts+promyelocytes in BM and PB, <20% basophils in PB, no extramedullary disease other than spleen and liver.
RTC < 15 % blastov v BM in PB, < 30 % blastov+promielocitov v BM in PB, < 20 % bazofilcev v PB, brez obolelosti zunaj kostnega mozga, razen v vranici in jetrih
Rua Carlos Alberto da Mota Pinto, 17, 3º A 1070-313 Lisboa (Portugal)
Rua Carlos Alberto da Mota Pinto, 17, 3º A 1070-313 Lisboa (Portugalska)
Rub gently into the area until the cream vanishes.
Kremo nežno vtirajte v kožo dokler ne izgine.
rub the injection site.
Na mesto injiciranja lahko tudi nalepite obliž.
Rubber membrane
Ščitnik
Rubber Seal
Gumijast a zaporka
Rubber stopper (under plastic cap)
gumijasti zamašek (pod plastičnim pokrovčkom)
Rubella virus Wistar RA 27/3 strain ............................................ ≥ 3.00 log10 CCID50
Virus rdečk, sev Wistar RA 27/3................................................................. ≥ 3,00 log10 CCID50
Rubella virus Wistar RA 27/3 strain ............................................ ≥ 3.00 log10 CCID50
Virus rdečk, sev Wistar RA 27/3...................................................................≥3,00 log10 CCID50
Rubella virus Wistar RA 27/3 strain ............................................ ≥ 3.00 log10 CCID50
Virus rdečk, sev Wistar RA 27/3................................................................≥3,00 log10 CCID50
Rubella virus Wistar RA 27/3 strain ............................................ ≥ 3.00 log10 CCID50
Virus rdečk, sev Wistar RA 27/3.............................................≥ 3,00 log10 CCID50
Rubella virus2 Wistar RA 27/3 strain (live, attenuated) not less than 3.00 log CCID *
Virus rdečk2, sev Wistar RA 27/3 (živ, oslabljen) najmanj 3,00 log CCID
Rubella virus2 Wistar RA 27/3 strain (live, attenuated)............... not less than 3.00 log10 CCID *
Virus rdečk2, sev Wistar RA 27/3 (živ, oslabljen) .............................. najmanj 3,00 log10 CCID
Rubella virus2 Wistar RA 27/3 strain (live, attenuated)............... not less than 3.00 log10 CCID *
Virus rdečk2, sev Wistar RA 27/3 (živ, oslabljen) ..............................najmanj 3,00 log10 CCID
Rubella virus2 Wistar RA 27/3 strain (live, attenuated)............... not less than 3.00 log10 CCID *
Virus rdečk2, sev Wistar RA 27/3 (živ, oslabljen)................................najmanj 3,00 log10 CCID
Ruconest 2100 U powder for solution for injection conestat alfa
Ruconest 2100 e. prašek za raztopino za injiciranje konestat alfa
Ruconest contains sodium
Zdravilo Ruconest vsebuje natrij.
Ruconest is a powder that is made up into a solution for injection.
Zdravilo Ruconest je prašek za pripravo raztopine za injiciranje.
Ruconest is given by slow injection into a vein lasting around five minutes.
Zdravilo Ruconest se daje s počasnim injiciranjem v veno približno pet minut.
Ruconest is not recommended for use during pregnancy or breast-feeding, unless the treating physician judges the benefits to outweigh the possible risks.
Zdravila Ruconest se ne priporoča za uporabo med nosečnostjo ali dojenjem, razen če lečeči zdravnik oceni, da pričakovane koristi prevladajo nad možnimi tveganji.
Ruconest is used in patients with hereditary angioedema that is linked to naturally low levels of a protein called ‘C1 esterase inhibitor’.
Zdravilo Ruconest se uporablja pri bolnikih z dednim angioedemom, ki je povezan z naravno nizkimi ravnmi beljakovine, imenovane zaviralec esteraze C1.
Ruconest is used to treat attacks of hereditary angioedema in adults and adolescents.
Zdravilo Ruconest se uporablja za zdravljenje napadov hereditarnega (dednega) angioedema pri odraslih in mladostnikih.
Ruconest must not be used in patients with known or suspected allergy to rabbits.
Zdravilo Ruconest se ne sme uporabljati pri bolnikih z znano ali domnevno alergijo na kunce.
Rue Bellocier, 89100, Sens,
Rue Bellocier, 89100 Sens
Rue de la Pastorale, 26-28 B-1080 Brussels
Rue de la Pastorale, 26-28 B-1080 Bruselj
Rue de Lyons 27460 Igoville FRANCE
Rue de Lyons 27460 Igoville FRANCIJA
Rue de l’Institut 89 B-1330 Rixensart Belgium
Rue de l’Institut 89 B-1330 Rixensart Belgija
Rue de Stalle, 73 B-1180 Bruxelles Belgium
Rue de Stalle, 73 B-1180 Bruxelles Belgija
Rue Laid Burniat 1 1348 Louvain-la-Neuve Belgium
Rue Laid Burniat 1 1348 Louvain-la-Neuve Belgija
Rue Laid Burniat 1 1348 Louvain-la-Neuve Belgium
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve Belgium
Rue Laid Burniat 1, 1348 Louvain-la-Neuve, BELGIUM
Rue Laid Burniat 1, 1348 Louvain-la-Neuve, BELGIJA
Rufinamide appears not to have clinically relevant effect on carbamazepine, lamotrigine, phenobarbital, topiramate, phenytoin or valproate steady state concentrations.
Zdi se, da rufinamid ni klinično pomembno vplival na koncentracije karbamazepina, lamotrigina, fenobarbitala, topiramata, fenitoina ali valproata v stanju dinamičnega ravnovesja.
Rufinamide has been shown to induce the cytochrome P450 enzyme CYP3A4 and may therefore reduce the plasma concentrations of substances which are metabolised by this enzyme.
Pokazali so, da rufinamid inducira encim CYP3A4 citokroma P450, in zato lahko zniža plazemske koncentracije učinkovin, ki jih presnavlja ta encim.
Rufinamide has demonstrated little or no significant capacity in-vitro to act as a competitive or mechanism-based inhibitor of the following human P450 enzymes: CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 or CYP4A9/11-2.
Rufinamid kaže malo ali nič signifikantne sposobnosti za delovanje in-vitro kot kompetitiven inhibitor ali inhibitor na podlagi mehanizma naslednjih človeških encimov, odvisnih od P450: CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 ali CYP4A9/11-2.
Rufinamide has demonstrated little or no significant capacity in-vitro to act as a competitive or mechanism-based inhibitor of the following human P450 enzymes: CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 or CYP4A9/11-2.
Rufinamid kaže malo ali nič signifikantne sposobnosti za delovanje in-vitro kot kompetitiven zaviralec ali zaviralec na podlagi mehanizma naslednjih človeških encimov, odvisnih od P450: CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 ali CYP4A9/11-2.
Rufinamide is for oral use.
Rufinamid se jemlje peroralno.
Run your finger along the adhesive pad to make sure that it sticks well.
S prstom potegnite preko lepljive podlage, da se bo res dobro prijela.
Running a diagnostic test of your pump system is needed if you think the pump may have been damaged by water, a sporting incident, electrotherapy (cardiac defibrillator), diagnostic ultrasound or radiation (X-ray).
Če sumite, da je prišlo do poškodbe črpalke zaradi vode, športne nezgode, elektroterapije (srčni defibrilator), diagnostičnega ultrazvoka ali obsevanja (rentgenski žarki), je treba opraviti diagnostični test sistema črpalke.
running nose
izcedek iz nosu
runny nose
izcedek iz nosu
runny nose
izcedek iz nosu,
Runny nose
izcejanje iz nosu,
runny nose
mrkavost
Runny nose
nahod
Runny nose
nahoden nos
runny nose (rhinitis)
nahod (rinitis)
runny nose (rhinitis)
prehlad (rinitis)
runny nose (rhinorrhoea)
izcedek iz nosu (rinoreja)
runny nose and sore throat
izcedek iz nosu in vnetje žrela,
Runny nose or nasal congestion
izcedek iz nosu ali zamašenost nosu,
Runny nose or sneezing
izcedek iz nosu ali kihanje,
runny nose,
izcedek iz nosu,
runny nose, cough, hoarseness due to infection of the upper respiratory tract,
izcedek iz nosu, kašelj, hripavost zaradi okužbe zgornjih dihal, vnetje sinusov, močnejši kašelj,
runny nose, cough, hoarseness due to infection of the upper respiratory tract, sinusitis, cough increased, shortness of breath (dyspnoea)
izcedek iz nosu, kašelj, hripavost zaradi okužbe zgornjih dihal, vnetje sinusov, močnejši kašelj, kratka sapa (dispneja)
runny nose, sore throat
izcedek iz nosu, vnetje žrela
runny nose.
izcedek iz nosu,
runny or blocked nose
izcedek iz nosu ali zamašen nos
runny or blocked nose (allergic rhinitis)
izcedek iz nosu ali zamašen nos (alergijski rinitis)
runny or bloody nose, sinus problems
izcedek ali krvavitev iz nosu, težave s sinusi
runny or stuffy nose
izcedek iz nosu ali zamašen nos
runny or stuffy nose
nahoden ali zamašen nos
runny or stuffy nose
nahoden ali zamašen nos,
runny or stuffy nose, sneezing
nahod ali zamašen nos, kihanje
runny or stuffy nose.
izcedek iz nosu ali zamašen nos
Runny/liquid stools
mehko/tekoče blato
Runny/liquid stools.
mehko/tekoče blato
rupture of a tendon, ligament injury
pretrganje kite, poškodba ligamenta (vezivno tkivo med kostmi);
rupture of the spleen
pretrganje vranice
rupture of the spleen
raztrganje vranice
Ruptured tendons.
pretrganje tetive,
RUTHERFORD-2 was an international, multicentre, double-blind, randomised, placebo-controlled, 12-week study in 329 patients with heterozygous familial hypercholesterolaemia on lipid-lowering therapies.
RUTHERFORD-2 je bila mednarodna, multicentrična, dvojno slepa, randomizirana, s placebom kontrolirana, 12-tedenska študija pri bolnikih s heterozigotno družinsko hiperholesterolemijo, zdravljenih z zdravili za zniževanje lipidov.
Ruxolitinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity and reproductive toxicity studies and in a carcinogenicity study.
Ruksolitinib so ocenjevali v študijah farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti in vpliva na sposobnost razmnoževanja ter v študiji kancerogenega potenciala.
Ruxolitinib is a Biopharmaceutical Classification System (BCS) class 1 compound, with high permeability, high solubility and rapid dissolution characteristics.
Po Biofarmacevtskem sistemu klasifikacije (Biopharmaceutical Classification System, BCS) sodi ruksolitinib v 1. razred spojin z dobro permeabilnostjo, dobro topnostjo in hitrim raztapljanjem.
Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes, respectively).
Ruksolitinib je selektivni zaviralec Janus kinaz (Janus Associated Kinases-JAK) JAK1 in JAK2 (vrednost IC50 za JAK1 encime je 3,3 nmol/l, za JAK2 encime pa 2,8 nmol/l).
Ruxolitinib may inhibit P-glycoprotein and breast cancer resistance protein (BCRP) in the intestine.
Ruksolitinib lahko zavira P-glikoprotein in protein rezistence pri raku dojke (angl. breast cancer resistance protein, BCRP) v črevesju.
RVR
odziv
RVR = rapid viral response (HCV RNA negative) by week 4 LVL = ≤ 800,000 IU/ml; HVL = > 800,000 IU/ml (a) It is presently not clear whether a higher dose of ribavirin (e.g.1000/1200 mg/day based on body weight) results in higher SVR rates than does the 800 mg/day, when treatment is shortened to 16 weeks.
1000/1200 mg na dan glede na telesno maso) povzroči višji delež trajnega virološkega odziva kot odmerek 800 mg na dan, kadar je zdravljenje skrajšano na 16 tednov.
RVR = rapid viral response (HCV RNA undetectable) at week 4 and HCV RNA undetectable at week 24
Hiter virološki odziv = nemerljiva koncentracija HCV RNA v tednu 4 in nemerljiva koncentracija HCV RNA v tednu 24
Rye ergot alkaloids (ergotamine, dihydroergotamine)
Alkaloidi rženega rožička (ergotamin, dihidroergotamin)
Ryzodeg
papirna
Ryzodeg (b.i.d.)1
Ryzodeg (2x/dan)1
Ryzodeg (b.i.d.)2
Ryzodeg (2x/dan)2
Ryzodeg (o.d.)2
Ryzodeg (1x/dan)2
Ryzodeg 100 units/mL solution for injection in cartridge
Ryzodeg 100 enot/ml raztopina za injiciranje v vložku
Ryzodeg 100 units/mL solution for injection in cartridge 70% insulin degludec / 30% insulin aspart
Ryzodeg 100 enot/ml raztopina za injiciranje v vložku 70 % insulina degludek/30 % insulina aspart
Ryzodeg 100 units/mL solution for injection in cartridge EU/1/12/806/007
Ryzodeg 100 enot/ml raztopina za injiciranje v vložku EU/1/12/806/007
Ryzodeg 100 units/mL solution for injection in cartridge insulin degludec/insulin aspart
Ryzodeg 100 enot/ml raztopina za injiciranje v vložku insulin degludek/insulin aspart
Ryzodeg 100 units/mL solution for injection in pre-filled pen
Ryzodeg 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Ryzodeg 100 units/mL solution for injection in pre–filled pen insulin degludec/insulin aspart
Ryzodeg 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku insulin degludek/insulin aspart
Ryzodeg administered once-daily (o.d.) plus Oral Anti-diabetic Drugs (OADs) was compared to insulin glargine (IGlar) (o.d.) plus OADs in two trials in type 2 diabetes mellitus (Table 1).
Zdravilo Ryzodeg enkrat na dan (1x/dan) v kombinaciji s peroralnimi antidiabetiki (POAD) so primerjali z insulinom glargin (IGlar) (1x/dan) v kombinaciji s POAD v dveh preskušanjih pri sladkorni bolezni tipa 2 (preglednica 1).
Ryzodeg allows for flexibility in the timing of insulin administration as long as it is dosed with the main meal(s).
Zdravilo Ryzodeg omogoča prilagodljivost v času apliciranja, pomembno je le, da si bolnik zdravilo aplicira ob glavnih obrokih.
Ryzodeg b.i.d. demonstrated similar glycaemic control (HbA1c) compared with BIAsp 30 b.i.d. in patients with type 2 diabetes mellitus.
Urejenost glikemije (HbA1c) pri bolnikih s sladkorno boleznijo tipa 2 je z zdravilom Ryzodeg 2x/dan podobna kot z BIAsp 30 2x/dan.
Ryzodeg can be administered once- or twice-daily with the main meal(s).
Zdravilo Ryzodeg se lahko aplicira enkrat ali dvakrat dnevno ob glavnih obrokih.
Ryzodeg can be used in adolescents and children from the age of 2 years (see section 5.1).
Zdravilo Ryzodeg se lahko uporablja pri mladostnikih in otrocih, starejših od 2 let (glejte poglavje 5.1).
Ryzodeg can be used in elderly but you may need to check your blood sugar level more often.
Zdravilo Ryzodeg se lahko uporablja pri starejših bolnikih, a si morate krvni sladkor kontrolirati pogosteje.
Ryzodeg can be used in elderly patients but you may need to check your blood sugar level more often.
Zdravilo Ryzodeg se lahko uporablja pri starejših bolnikih, a si morate krvni sladkor kontrolirati pogosteje.
Ryzodeg can be used in the elderly.
Zdravilo Ryzodeg se lahko uporablja pri starejših bolnikih.
Ryzodeg can either be used once or twice each day.
Zdravilo Ryzodeg se lahko uporabi enkrat ali dvakrat na dan.
Ryzodeg cartridge 100
Ryzodeg vložek 100
Ryzodeg comes in a cartridge (Penfill) designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist injection needles.
Zdravilo Ryzodeg je na voljo v vložku (Penfill) in je namenjeno za uporabo s sistemi za dajanje insulina Novo Nordisk in injekcijskimi iglami NovoFine ali NovoTwist.
Ryzodeg comes in a pre-filled pen (FlexTouch) designed to be used with NovoFine or NovoTwist injection needles.
Zdravilo Ryzodeg je na voljo v napolnjenem injekcijskem peresniku (FlexTouch) in je namenjeno za uporabo z injekcijskimi iglami NovoFine ali NovoTwist.
Ryzodeg contains two types of insulin:
Zdravilo Ryzodeg vsebuje dve vrsti insulina:
Ryzodeg has a rapid onset of action occurring soon after injection providing meal time coverage while the basal component has a flat and stable action profile providing continuous coverage of the basal insulin requirements.
Zdravilo Ryzodeg začne delovati hitro po injiciranju in krije potrebo po insulinu ob obrokih, bazalna sestavina pa ima enakomeren in stabilen profil delovanja, ki zagotavlja stalno kritje potreb po bazalnem insulinu.
Ryzodeg is a soluble insulin product consisting of the basal insulin degludec and the rapid-acting prandial insulin aspart.
Ryzodeg je topno insulinsko zdravilo, sestavljeno iz bazalnega insulina degludek in hitrodelujočega prandialnega insulina aspart.
Ryzodeg is for subcutaneous use only.
Zdravilo Ryzodeg je namenjeno zgolj subkutani uporabi.
Ryzodeg is given as an injection under the skin (subcutaneous injection).
Zdravilo Ryzodeg je namenjeno injiciranju pod kožo (subkutano injiciranje).
Ryzodeg is presented as a clear and colourless solution for injection in a cartridge (300 units per 3 mL).
Zdravilo Ryzodeg je na voljo kot bistra in brezbarvna raztopina za injiciranje v vložku (300 enot v
Ryzodeg is presented as a clear and colourless solution for injection in pre-filled pen (300 units per 3 mL).
Zdravilo Ryzodeg je na voljo kot bistra in brezbarvna raztopina za injiciranje v napolnjenem injekcijskem peresniku (300 enot v 3 ml).
Ryzodeg is to be dosed in accordance with the individual patient’s needs.
Zdravilo Ryzodeg je treba odmerjati glede na potrebe posameznega bolnika.
Ryzodeg is used to treat diabetes mellitus in adults, adolescents and children from the age of 2 years.
Zdravilo Ryzodeg se uporablja za zdravljenje sladkorne bolezni pri odraslih, mladostnikih in otrocih, starejših od 2 let.
Ryzodeg may be associated with higher occurrence of severe hypoglycaemia compared to a basal-bolus regimen in paediatric population, particularly in children 2 to 5 years old (see section 5.1).
Pri pediatrični populaciji, še posebej pri otrocih, starih od 2 do 5 let, je uporaba zdravila Ryzodeg lahko povezana z večjo pojavnostjo hude hipoglikemije v primerjavi z bazalno-bolusno shemo (glejte poglavje 5.1).
Ryzodeg must not be administered intramuscularly as it may change the absorption.
Zdravila Ryzodeg se ne sme aplicirati intramuskularno, ker lahko povzroči spremembo v absorpciji.
Ryzodeg must not be administered intravenously as it may result in severe hypoglycaemia.
Zdravila Ryzodeg se ne sme aplicirati intravensko, ker lahko povzroči hudo hipoglikemijo.
Ryzodeg must not be used if the solution does not appear clear and colourless.
Zdravila Ryzodeg ne smete uporabiti, če raztopina ni bistra in brezbarvna.
Ryzodeg must not be used in insulin infusion pumps.
Zdravila Ryzodeg se ne sme uporabljati v infuzijskih črpalkah za insulin.
Ryzodeg o.d. plus insulin aspart (IAsp) was also compared to once-daily (o.d.) or twice-daily insulin detemir (IDet) plus IAsp in type 1 diabetes mellitus (Table 3).
Zdravilo Ryzodeg 1x/dan v kombinaciji z insulinom aspart (IAsp) so primerjali tudi s kombinacijo insulina detemir (IDet) in IAsp 1x/dan ali 2x/dan pri sladkorni bolezni tipa 1 (preglednica 3).
Ryzodeg plus OADs was compared to biphasic insulin aspart 30 (BIAsp 30) b.i.d. plus OADs in two trials in type 2 diabetes mellitus (Table 2).
Zdravilo Ryzodeg dvakrat na dan (2x/dan) v kombinaciji s POAD so primerjali z dvofaznim insulinom aspart 30 (BIAsp 30) 2x/dan v kombinaciji s POAD v dveh preskušanjih pri sladkorni bolezni tipa 2 (preglednica 2).
Ryzodeg pre-filled pen 100
Ryzodeg peresnik 100
Ryzodeg which has been frozen must not be used.
Zdravila Ryzodeg, ki je bilo zamrznjeno, ne smete uporabiti.
Równoległa 5 02-235 Warszawa Poland
Równoległa 5 02-235 Warszawa Poljska
Równoległa 5, 02-235 Warszawa, Poland KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
Równoległa 5, 02-235 Warszawa, Poljska KRKA – FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Hrvaška
Równoległa 5, 02-235 Warszawa, Poland TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany KRKA – FARMA d.o.o.,V. Holjevca 20/E, 10 450 Jastrebarsko, Croatia
Równoległa 5, 02-235 Warszawa, Poljska TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Nemčija KRKA – FARMA d.o.o.,V. Holjevca 20/E, 10450 Jastrebarsko, Hrvaška
S 400 mg
400 mg
S  0.25 mg/L and R  0.5 mg/L
S  0,25 mg/l in R > 0,5 mg/l
S  0.5 mg/L and R  0.5 mg/L
S  0,5 mg/l in R > 0,5 mg/l
S  1 mg/l and R > 1 mg/l
S  1 mg/l in R > 1 mg/l
S" is on the 3.6 mg tablets, "M" on the 5.4 mg tablets, and "L" on the 16 mg tablets.
S" je na 3,6-mg tabletah, "M" na 5,4-mg tabletah in "L" na 16-mg tabletah.
S-151 85 Södertälje Sweden
SE-151 85 Södertälje
S-151 85 Södertälje Sweden
SE-151 85 Södertälje Švedska
S-Ibuprofen AUC0-  100%
S-ibuprofen AUC0-  100
S-Ibuprofen Cmax  20%
S-ibuprofen Cmax  20
S-methadone Cmax ↓ 62% S-methadone AUC ↓ 63%
Cmax S-metadona ↓ 62% AUC S-metadona ↓ 63
S-methoprene (mg)
(S)-metopren (mg)
S-posti: medical.information@themedco.com
E-post : medical.information@themedco.com
S-PSUR submission to the Rapporteur and CHMP members on Day 45.
Predaja poročil S-PSUR poročevalcu in članom odbora CHMP bo opravljena na 45. dan.
S-PSUR submission to the Rapporteur and CHMP members on Day 45.
Predložitev S-PSUR poročevalcu in članom Odbora za zdravila za uporabo v humani medicini (CHMP) 45. dan.
S-PSUR submission to the Rapporteur and CHMP members on Day 45.
S-PSUR je poročevalcu in članom CHMP oddano 45. dan.
S-warfarin AUC 1.04 (1.00-1.07) ↔
pride do blagega zvečanja koncentracij
S-warfarin AUC ↑ 18%
AUC S-varfarina ↑ 18
S-warfarin AUC ↓ 12%
AUC varfarina ↓ 12
S-warfarin Cmax 1.00 (0.94-1.06) ↔
Režimi zdravljenja s
S-warfarin pharmacokinetics were evaluated following a single dose of warfarin 25mg given alone, or administered at the start, 24, or 72 hours after a single 1200mg dose of oritavancin.
Farmakokinetiko S-varfarina so ocenili po posameznem odmerku varfarina 25 mg v monoterapiji ali pa na začetku, 24 ali 72 ur po posameznem 1200 mg odmerku oritavancina.
S. aureus (all)
S. aureus (vsi)
S. aureus) exhibited natural in vitro resistance to cefovecin
S. aureus) so pokazali naravno in vitro rezistenco na cefovecin
S. pneumoniae S  1 mg/l and R > 1 mg/l
S. pneumoniae S  1 mg/l in R > 1 mg/l
S. pseudintermedius and beta-haemolytic Streptococci isolates was less than 0.02 % and 3.4 % in Prevotella intermedia isolates.
S. psudintermedius in beta-hemolitičnih Streptococci izolatih manj kot 0,02 % in 3,4 % pri Prevotella intermedia izolatih.
S. xylosus, S. schleiferi, S. epidermidis) is 9.5 %.
S. xylosus, S. schleiferi, S. epidermidis) je 9,5 %.
S.A. Alcon-Couvreur N.V
S.A. Alcon - Couvreur N.V.
S.C. injection
s.c. injekcija
s.c. injection or i.m. injection of one dose of 0.25 ml.
En odmerek po 0,25 ml s.c. ali i.m.
S.C. Sindan-Pharma S.R.L. 11 Ion Mihalache Blvd Bucharest
S.C. Sindan-Pharma S.R.L. 11 Ion Mihalache Blvd Bukarešta
S345X
R342L
S401X
E398X
S405R
W399X
SAA study population
Študijska populacija s hudo aplastično anemijo
Sabe rvel contains lactose.
Zdravilo Sabe rvel vsebuje laktozo.
Sabervel 150 mg film-coated tablets
Sabervel 150 mg filmsko obložene tablete.
Sabervel 150 mg film-coated tablets are white, concave, round, film-coated tablets with 9 mm diameter.
Sabervel 150 mg filmsko obložene tablete so bele, konkavne, okrogle, s premerom 9 mm.
Sabervel 150 mg film-coated tablets irbesartan
Sabe rvel 150 mg filmsko obložene tablete irbesartan
Sabervel 300 mg film-coated tablets
Sabervel 300 mg filmsko obložene tablete.
Sabervel 300 mg film-coated tablets are white, concave, round, film-coated tablets with 11 mm diameter.
Sabervel 300 mg filmsko obložene tablete so bele, konkavne, okrogle, s 11 premerom mm.
Sabervel 300 mg film-coated tablets irbesartan
Sabe rvel 300 mg filmsko oblože ne table te irbesartan
Sabervel 75 mg film-coated tablets
Sabervel 75 mg filmsko obložene tablete.
Sabervel 75 mg film-coated tablets are white, concave, round, film-coated tablets with 7 mm diameter.
Sabervel 75 mg filmsko obložene tablete so bele, konkavne, okrogle, s premerom 7 mm.
Sabervel 75 mg film-coated tablets irbesartan
Sabe rvel 75 mg filmsko obložene tablete irbesartan
Sabervel belongs to a group of medicines known as angiotensin-II receptor antagonists.
Zdravilo Sabervel spada v skupino zdravil, ki so znana kot antagonisti angiotenzina-II.
Sabervel can be taken with or without food.
Zdravilo Sabervel lahko jemljete s hrano ali brez nje.
Sabervel is a ‘generic medicine’.
Zdravilo Sabervel je „generično zdravilo“.
Sabervel is for oral use .
Zdravilo Sabervel je potrebno zaužiti.
Sabervel is indicated in adults for the treatment of essential hypertension.
Zdravilo Sabervel je indicirano pri odraslih za zdravljenje esencialne hipertenzije.
Sabervel slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 zdravilo Sabervel upočasni pešanje delovanja ledvic.
Saccharin sodium
natrijev saharinat
Saccharin sodium Carmellose sodium
natrijev saharinat
Saccharin sodium Carmellose sodium
natrijev saharinat natrijev karmelozat
Saccharin sodium powder Purified water
Natrijev saharinat, prah Prečiščena voda